It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Colloidal gold nanoparticles (GNPs) serve as promising contrast agents in photoacoustic (PA) imaging, yet their utility is limited due to their absorption peak in the visible window overlapping with that of hemoglobin. To overcome such limitation, this report describes an ultrapure chain-like gold nanoparticle (CGNP) clusters with a redshift peak wavelength at 650 nm. The synthesized CGNP show an excellent biocompatibility and photostability. These nanoparticles are conjugated with arginine-glycine-aspartic acid (RGD) peptides (CGNP clusters-RGD) and validated in 12 living rabbits to perform multimodal photoacoustic microscopy (PAM) and optical coherence tomography (OCT) for visualization of newly developed blood vessels in the sub-retinal pigment epithelium (RPE) space of the retina, named choroidal neovascularization (CNV). The PAM system can achieve a 3D PAM image via a raster scan of 256 × 256 pixels within a time duration of 65 s. Intravenous injection of CGNP clusters-RGD bound to CNV and resulted in up to a 17-fold increase in PAM signal and 176% increase in OCT signal. Histology indicates that CGNP clusters could disassemble, which may facilitate its clearance from the body.
This manuscript presents ultrapure chain-like gold nanoparticle clusters with red shifted absorption and shows their potential for in vivo imaging in living rabbits. The nanoparticles demonstrate a 17-fold increase in photoacoustic microscopy signal and 176% increase in optical coherence tomography signal.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Michigan, Department of Ophthalmology and Visual Sciences, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); NTT-Hitech Institutes, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam (GRID:grid.473736.2) (ISNI:0000 0004 4659 3737)
2 IMRA America, Inc., Ann Arbor, USA (GRID:grid.472501.5)
3 University of Michigan, Department of Ophthalmology and Visual Sciences, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
4 University of Michigan, Department of Biomedical Engineering, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
5 University of Michigan, Department of Ophthalmology and Visual Sciences, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); University of Michigan, Department of Biomedical Engineering, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)